Suppliers and packagers for METHYLPREDNISOLONE SODIUM SUCCINATE

METHYLPREDNISOLONE SODIUM SUCCINATE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Amneal	METHYLPREDNISOLONE SODIUM SUCCINATE	methylprednisolone sodium succinate	INJECTABLE;INJECTION	207549	ANDA	Amneal Pharmaceuticals LLC	70121-1000-5	25 VIAL in 1 CARTON (70121-1000-5) / 1 mL in 1 VIAL (70121-1000-1)	2016-11-11
Amneal	METHYLPREDNISOLONE SODIUM SUCCINATE	methylprednisolone sodium succinate	INJECTABLE;INJECTION	207549	ANDA	Amneal Pharmaceuticals LLC	70121-1001-5	25 VIAL in 1 CARTON (70121-1001-5) / 2 mL in 1 VIAL (70121-1001-1)	2016-11-11
Eugia Pharma	METHYLPREDNISOLONE SODIUM SUCCINATE	methylprednisolone sodium succinate	INJECTABLE;INJECTION	207667	ANDA	Eugia US LLC	55150-262-03	25 VIAL, SINGLE-DOSE in 1 CARTON (55150-262-03) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL, SINGLE-DOSE	2015-12-15

Suppliers and packagers for METHYLPREDNISOLONE SODIUM SUCCINATE

Last updated: May 23, 2026

Methylprednisolone Sodium Succinate Suppliers: API, Intermediates, and Contract Manufacturing for Injectable Sterile Products

Methylprednisolone sodium succinate (MPSS) is supplied through a mix of branded manufacturers, generic sterile-injectable producers, and API makers that sell into sterile fill-finish and packaging networks. The supplier landscape is split by role: active pharmaceutical ingredient (API) makers, sterile drug product manufacturers (lyophilized and liquid), and component and packaging suppliers (vials, stoppers, seals). MPSS procurement is typically managed through qualification of both the API and the finished sterile product, including DMF/ASMF status, sterile manufacturing controls, and container closure system validation.

Who supplies methylprednisolone sodium succinate injectable products in the US market?

Answer: US supply is dominated by generic sterile manufacturers and branded original suppliers that sell MPSS vials under multiple labelers. MPSS is widely distributed as a sterile injectable, commonly in vial strengths (for example 40 mg/mL equivalent and higher-dose vials, depending on labeler and product configuration).

Which companies commonly act as drug product labelers or sterile manufacturers?

MPSS is sold by multiple companies that act as marketing authorization holders for generic injectable products. In practice, many labelers source API from established chemical producers and contract fill-finish to sterile manufacturing sites. The supplier set changes frequently by portfolio and sourcing strategy.

What generic product presentations exist that drive supply chain differences?

Supplier selection varies by:

• Liquid vs lyophilized (if offered for the same strength)
• Single-dose vial presentation
• Container closure system (rubber stoppers, seals)
• Sterile filtration and aseptic processing vs terminal sterilization approaches used by a given site

What companies supply methylprednisolone sodium succinate API (active pharmaceutical ingredient) globally?

Answer: MPSS API is typically produced by chemical synthesis and sold under DMF/ASMF to sterile injectable manufacturers. API supply is less visible than finished product supply, but it is the bottleneck for qualified producers.

How do API suppliers usually provide documentation for injectable use?

Sterile-injectable producers qualify API using:

• DMF/ASMF filings and updates
• CoA-based release testing and impurity profile matching
• Stability data under ICH conditions
• GMP compliance history and inspection outcomes

What drives which API suppliers get used for US injectable filings?

• Ability to support cGMP for injectable-grade API
• Consistency in impurity and moisture control
• Access to the same polymorph/particle and appropriate salt quality attributes (as applicable)
• Supply reliability for batch cadence relative to sterile line capacity

Which suppliers provide contract manufacturing and sterile fill-finish for MPSS vials?

Answer: sterile fill-finish is frequently performed by contract manufacturing organizations (CMOs) that support aseptic manufacturing and packaged drug product release testing. For MPSS, procurement often routes through CMO networks that already support corticosteroid injectables.

What manufacturing capabilities matter for methylprednisolone sodium succinate sterile products?

• Aseptic processing (when used) with validated sterilizing-grade filtration steps
• Container closure system validation for vial + stopper + seal
• Particulate and endotoxin testing workflows sized for batch volumes
• Extractables/leachables assessment and compatibility with MPSS formulation
• Traceability and labeling serialization readiness (where required)

How does formulation and packaging affect CMO selection?

MPSS vial products rely on specific excipient and pH systems to maintain solubility and stability. These formulation specifics determine which CMO’s historical process controls can be used without bridging.

How can procurement teams identify reliable methylprednisolone sodium succinate suppliers?

Answer: qualifying suppliers for MPSS typically requires evaluating both API provenance and finished sterile GMP performance. Procurement diligence is usually structured around the DMF/ASMF trail, inspection history, and batch-to-batch analytical consistency.

Qualification checklist used in sterile injectable sourcing

• DMF/ASMF holder and version alignment for the specific API grade
• GMP certificate of compliance for the API site and sterile site
• Evidence of validated sterilization/aseptic process and environmental monitoring controls
• Container closure system compatibility package
• Documentation turnaround time for CoA, batch records, and stability summaries
• Regulatory submission alignment (labeling, strength, overfill, fill volume targets)

What do methylprednisolone sodium succinate supply contracts usually cover (API vs finished product)?

Answer: contracts often split into two layers: API supply agreements plus finished drug product manufacturing and release agreements. Where the sterile manufacturer buys API directly, the contract must still cover analytical method transfers and impurity thresholds.

Common contract structures

• API-only agreements from qualified DMF/ASMF-backed suppliers to multiple fill-finish sites
• Full program agreements where a CMO supplies both manufacture and packaged finished goods release
• Dual sourcing strategies for continuity during sterile line disruptions

Where do supply bottlenecks typically occur for MPSS?

Answer: bottlenecks concentrate on qualified sterile line capacity and on consistent API impurity profiles for injectable-grade material.

Bottleneck drivers

• Limited number of qualified sterile lines for injectable corticosteroids in specific vial formats
• Inspection findings that force remediation and delay approvals or batch releases
• API quality excursions linked to impurity control and drying/handling constraints
• Container closure shortages impacting stopper/seal lead times

What is the competitive landscape for methylprednisolone sodium succinate generics?

Answer: the competitive set includes multiple generic injectables labelers, often competing on manufacturing site capacity, lead times, and product distribution reliability rather than on clinical differentiation.

What does “competition” mean in MPSS tendering?

• Lowest-cost qualified supplier wins tenders
• Backup suppliers are pre-qualified to reduce stockout risk
• Contract terms emphasize delivery schedules, fill-finish batch cadence, and regulatory compliance

How does supplier quality impact regulatory outcomes for methylprednisolone sodium succinate?

Answer: supplier GMP and analytical consistency are direct drivers of CMC approval performance and inspection outcomes. For MPSS injectables, regulators focus on sterility assurance, impurities, and container closure suitability.

Key CMC themes that can block supply

• Failure to match impurity profiles to the registered API specifications
• Unvalidated changes in synthesis route, solvent systems, or drying conditions
• Container closure incompatibility leading to stability failures
• Sterile process deviations that require batch rejection or batch holds

Key Takeaways

• MPSS supply is split into API suppliers and sterile drug product manufacturers, with procurement success depending on qualification of both layers.
• The most material qualification barriers are consistent injectable-grade API quality, validated sterile manufacturing, and container closure system compatibility.
• Supplier availability and pricing in MPSS tenders are driven by sterile line capacity, regulatory cleanliness of the manufacturing network, and continuity of API impurity control.
• Effective sourcing relies on dual sourcing for API and backup sterile release capacity to manage lead time and stockout risk.

FAQs

1) Are methylprednisolone sodium succinate suppliers the same as other corticosteroid injectable suppliers?
Often partially overlapping, but MPSS sourcing is commonly qualified separately due to product-specific CMC controls and impurity specifications.

2) What matters more for MPSS supply: API supplier qualification or sterile fill-finish site qualification?
Both are critical; sterile release qualification is often the binding constraint because it determines batch acceptability for market release.

3) How do procurement teams validate container closure compatibility for MPSS vials?
They require CCI assessments, extractables/leachables data, and stability evidence aligned to the specific vial, stopper, and seal combination.

4) What documents do tenders typically ask for from MPSS suppliers?
CoA history, GMP certificates, DMF/ASMF alignment, batch record summaries, release testing methods, and stability documentation.

5) Do MPSS supply disruptions usually originate in API production or sterile manufacturing?
Disruptions more commonly surface from sterile manufacturing constraints and batch release issues, though API impurity or supply consistency can also be decisive.

References

No sources were provided in the prompt, and no verified supplier list or named company set can be produced without introducing unsupported claims.